-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QF35EoVXPJP0fouj0BXF08Jaa5uetg2WPN/I3oqEC1S1/NeKFyhV6EEDrBTYLuH3 gg0Oz50A5vJ/cvNPXAnDfA== 0001209191-06-055110.txt : 20061018 0001209191-06-055110.hdr.sgml : 20061018 20061018142858 ACCESSION NUMBER: 0001209191-06-055110 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061017 FILED AS OF DATE: 20061018 DATE AS OF CHANGE: 20061018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Trubion Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001298521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: 2401 14TH AVENUE STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2068380500 MAIL ADDRESS: STREET 1: 2401 14TH AVENUE STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHNELL DAVID CENTRAL INDEX KEY: 0001162060 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33054 FILM NUMBER: 061150639 BUSINESS ADDRESS: BUSINESS PHONE: 650-470-8116 MAIL ADDRESS: STREET 1: 435 TASSO STREET STREET 2: SUITE 200 CITY: PALO ALTO STATE: CA ZIP: 94301 3 1 bos24291_bos01ds.xml MAIN DOCUMENT DESCRIPTION X0202 3 2006-10-17 0 0001298521 Trubion Pharmaceuticals, Inc TRBN 0001162060 SCHNELL DAVID C/O PROSPECT VENTURE PARTNERS 435 TASSO STREET, SUITE 200 PALO ALTO CA 94301 1 0 0 0 Series B Convertible Preferred Stock Common Stock 1795112 I By Prospect Venture Partners II, L.P. Series B Convertible Preferred Stock Common Stock 27338 I By Prospect Associates II, L.P. Each share of Preferred Stock is convertible and will automatically convert on a 1:1 basis into the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock pursuant to an effective registration statement filed with the U.S. Securities and Exchange Commission. These shares have no expiration date. The shares are owned by Prospect Venture Partners II, L.P. ("PVP II"). Prospect Management Co. II, L.L.C. ("PMC II") serves as the sole general partner of PVP II. James B. Tananbaum, M.D., Alexander E. Barkas, Ph.D., David Schnell, M.D., and Russell C. Hirsch, M.D., Ph.D. are the Managing Directors of PMC II. The reporting person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest. The shares are owned by Prospect Associaties II, L.P. ("PA II"). PMC II serves as the sole general partner of PA II. James B. Tananbaum, M.D., Alexander E. Barkas, Ph.D., David Schnell, M.D., and Russell C. Hirsch, M.D., Ph.D. are the Managing Directors of PMC II. The reporting person disclaims beneficial ownership of the shares reported herein, except to the extent of its pecuniary interest. /s/ David Schnell M.D. 2006-10-17 -----END PRIVACY-ENHANCED MESSAGE-----